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Abstract 
 
 
 The atypical antipsychotics are a group of second generation drugs used for 
the treatment of schizophrenia, schizoaffective disorder, as well as some forms of 
bipolar and major depressive disorder. First generation or the “typical antipsychotics” 
are an older group of drugs whose first member, chlorpromazine was developed in the 
early 1950’s. The typical antipsychotics have a higher propensity to induce 
extrapyramidal side effects (EPS), and elevate prolactin levels. The introduction to 
this thesis begins with the history of the typical antipsychotics; particularly the 
introduction of chlorpromazine, up to the introduction of clozapine a compound 
which revolutionized the treatment of schizophrenia.  Then the five subsequently 
approved atypical antipsychotic drugs are discussed.  The introduction of clozapine 
soon revealed agranuocytosis as a relatively frequent side effect, and  made it clear 
that a need remains for antipsychotics that are equally or more efficacious without 
deadly leukocytopenic side effects. While the atypical antipsychotics are often 
lumped into one category, they are diverse compounds with different EPS liabilities, 
side effects, and pharmacodynamic properties. Thus, the pharmacology of the 
atypical antipsychotics and the most interesting set of side effects, the extrapyramidal 
side effects are reviewed. Extrapyramidal side effects include akathisia, 
parkinsonism, dystonia, and tardive dyskinesia, and are complex motor side effects 
with mental components. This set of troublesome side effects often result in 
compliance issues particularly with the typical antipsychotics. Dopamine D2 receptor 
antagonism in the nigrostriatal pathways of the brain is believed to be the primary 
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cause of extrapyramidal side effects. Dopamine D2 receptor antagonism in the 
mesolimbic dopamine pathway is thought to result in the antipsychotic affect, and 
compounds that target this pathway selectively are hypothesized to have lower EPS 
liabilities. Although the atypical antipsychotics are a diverse group of drugs they have 
some common features including lower extrapyramidal side effect liabilities, and 
minimal or no prolactin elevation. Within this context two major hypothesis’ of 
atypicality will be reviewed, the fast-dissociation hypothesis and 5-HT2A/D2 affinity 
ratio hypothesis. Orolingual components of extrapyramidal side effects will be 
reviewed as well as neural control of the tongue by the hypoglossal nucleus, 
hypoglossal nucleus organization, and tongue anatomy, and physiology.   Relevant 
preclinical behavioral research of both typical and atypical antipsychotics will be 
reviewed.  The research presented here is concerned with both the acute and 
subchronic effects of the atypical antipsychotic on orolingual function in rats as a 
model of EPS.  Licking behavior in rats is believed to be controlled by central pattern 
generators in the brainstem, and the rhythm (Hz) of licking, peak force, and the 
number of licks will be quantitatively analyzed and compared. Tolerance and 
sensitization will be assessed using a subchronic dosing regimen. These data will then 
be discussed in the context of past studies concerning licking dynamics with 
haloperidol and clozapine, and to a lesser extent risperidone.
1 
 
Introduction 
 
In the early 1950’s the drug chlorpromazine was introduced and was 
originally used for preoperative anxiety (1). A series of animal studies and clinical 
observations built a foundation of knowledge about chlorpromazine, which lead to it 
being the first antipsychotic drug used for the treatment of schizophrenia. In 1950, 
Courvoisier and colleagues observed that chlorpromazine had pronounced effects on 
the central nervous system, including the prolongation of sleep induced by 
barbiturates in rodents, the prevention of apomorphine-induced emesis in canines, and 
the inhibition of the conditioned avoidance-escape behavioral response in mice (3). In 
1951, Laborit and Huguenard observed that surgical patients could be induced into a 
state of "artificial hibernation" by a "lytic cocktail" of chlorpromazine, promethazine 
when administered in combination with an analgesic.  It was also observed that 
patients treated with this cocktail required lower doses of anesthetisia and were more 
capable of coping with the stress of surgical trauma. (3,4,5).  Based on these 
observations of the CNS effects of chlorpromazine, Laborit and Huguenard provided 
chlorpromazine to two groups of psychiatrists. Chlorpromazine was given to Hamon, 
Paraire, and Velluz at the Central Military Hospital, in Paris (5) and Delay, Deniker, 
and Harl at the psychiatric clinic of Sainte Anne Hospital in Paris (3,6,7) .  The first 
reported chlorpromazine-treated case was a 57-year-old laborer who was admitted to 
the Central Military Hospital because of erratic, uncontrollable behavior (25, 26). 
Shortly after the administration of chlorpromazine his symptoms were improved, 
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chlorpromazine was recognized for its effects on the mentally ill, and a clinical 
breakthrough had occurred. 
The clinical success of chlorpromazine stimulated research, which led to 
many other drugs that were marketed for the treatment of schizophrenia, such as 
thioridazine, fluphenazine, and haloperidol. However, in 1954, two years after 
chlorpromazine first came into clinical use, extrapyramidal side effects (EPS) 
including Parkinsonism, dystonias, and akathisia began to be described and 
recognized as side effects of chlorpromazine (8).  A 1961 study reported the 
prevalence of EPS in patients treated with typical antipsychotic drugs was estimated 
at 38.9% (9). The majority of clinicians and pharmacologists became convinced that 
EPS was associated with the clinical effectiveness of antipsychotic drugs (10,11). 
This attitude was reinforced by introduction of haloperidol in 1958 by Haase and 
Janssen, a drug that is both effective in the treatment of schizophrenia but also 
frequently induced EPS (10,11).  
In the early 1960’s German psychiatrists working with G. Stille at Wander 
Pharmaceuticals in Bern, Switzerland, were able to refute the concept that EPS was 
required for the efficacy of antipsychotic drugs through the development of clozapine 
(12).  Clozapine, a second generation antipsychotic is only minimally associated with 
EPS (13). Clozapine was briefly marketed and quickly withdrawn (13), because it 
lacked the propensity to induce EPS believed necessary for therapeutic efficacy. 
Clozapine use was further limited by the purchase of Wander Pharmaceuticals by 
Sandoz Pharmaceuticals (14) and, most significantly, reports from Finland that life-
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threatening incidents of agranulocytosis associated with clozapine treatment (15).  
However, enthusiasm for the drug was maintained by a few clinical investigators, 
notably G. Honigfeld at Sandoz, who observed that clozapine was remarkably 
effective in treatment-resistant schizophrenic patients. This observation led to the 
landmark double-blind clinical study of clozapine using a well defined group of 
treatment-resistant patients whose blood cell counts were closely monitored during 
treatment, (16) and ultimately to its introduction to the US market in 1990.  
Clozapines’ success stimulated the development of other second generation 
antipsychotic drugs with similar efficacy with the idea of eliminating leukocytopenic 
side effects. The first of these, risperidone, was approved in 1994, (17) olanzapine 
followed in 1996, (18) quetiapine in 1997 (19), ziprasidone in 2001 (56), and 
aripiprazole in 2002 (55). All subsequently released atypical antipsychotic drugs have 
yet to prove that they are as effective as clozapine, which is still considered the most 
efficacious drug for the treatment of schizophrenia. (13). 
 
Pharmacology of Antipsychotic Drugs 
 
 The antagonism of dopamine D2 receptors is believed to be the most important 
pharmacodynamic attribute of both the typical and atypical antipsychotics.  
Antagonism of D2 receptors affects three main dopaminerigic pathways in the brain: 
the mesolimbic, nigostriatal, and tuberoinfudibular (79). The mesolimbic tract 
originates in the A10 area and innervates both cortical and limbic structures. 
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Mesolimbic dopaminerigic projections appear to be important in arousal, memory, 
stimulus processing, locomotor activity and motivational behavior.  The positive 
symptoms of schizophrenia (hallucinations and delusions) are believed to be 
associated with hyperdopaminergic activity in the limbic system, thus it is likely that 
D2 antagonism in the mesolimbic tract alleviates theses symptoms by reducing its 
dopaminerigic tone (79).  
 The nigrostriatal pathway originates in area A9 (zona compacta) and projects 
through the basal ganglia, and the blockade of D2 receptors in this pathway is 
believed to be primarily responsible for Parkinsonism and other extrapyramidal side 
effects. The basal ganglia of the nigrostriatal pathway are thought to be involved in 
motor learning and movement sequencing.   The tuberoinfudibular tract has its cell 
bodies in the hypothalamus and projects to the pituitary gland where it regulates the 
release of prolactin. Lactotrophs of anterior pituitary posses D2 receptors that when 
stimulated by dopaminerigic projections inhibit prolactin secretion. Antagonism of 
the D2 receptors of pituitary lactotrophs interferes with the dopaminerigic stimulation 
from tuberoinfudibular tract neurons and disinhibits the regulation of lactrotrophs 
resulting in the elevation of prolactin secretions (79). Prolactin elevation is a 
prominent side effect of the typical antipsychotics and to a much lesser extent the 
atypical antipsychotics.   
Antagonism of cortical 5-HT2 receptors in the cortex is believed to release 
tonic inhibition of dopaminerigic neurons and improve the hypodopaminergic frontal 
cortex found in schizophrenic patients (79). This mechanism may contribute to the 
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improved negative and cognitive symptoms of schizophrenic patients using the 
atypical antipsychotics.   
 
Theories of Atypicality 
 
 Dopamine D2 receptor blockade is a pharmacodynamic property of all 
antipsychotics, both typical and atypical, with the exception of aripiprazole, which is 
a D2 receptor partial agonist (27). While the definition of atypical antipsychotics has 
not been solidified and is generally used as a blanket term to describe second 
generation antipsychotics, there are differences that distinguish the typical from 
atypical. The most obvious include lower EPS liability, none to minimal prolactin 
elevation, and a higher affinity for 5-HT2A receptors than D2 receptors. However, 
these parameters vary greatly among the atypical antipsychotics and provide only a 
loose definition. Several individuals have attempted to define the atypical nature of 
these second generation antipsychotics, and this work has led to two major 
hypotheses.   
The two hypotheses that have been put forth in attempt to define atypicality 
are the fast dissociation hypothesis and the 5-HT2A/D2 affinity ratio hypothesis. The 
fast dissociation hypothesis is based of the fact that all antipsychotics antagonize D2 
receptors but that the atypicals dissociate more quickly from the receptors than the 
typicals. This hypothesis states that rapid dissociation of atypicals from D2 receptors 
is the property that results in lower EPS liabilities and minimal prolactin elevation 
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and is the key pharmacodynamic property of atypicality (57). Photon emission 
tomography studies have shown that the threshold for inducing EPS is at about 80% 
nigrostriatal D2 receptor occupancy in the, while antipsychotic activity only requires 
around 65% D2 occupancy (58). Faster dissociation would result in a lower 
occupancy percentage at any given moment, and a lower incidence of EPS, as well as 
lower percentage occupancy producing the desired therapeutic results. One of the 
major weaknesses of this hypothesis is that it only takes into account D2 receptor 
interactions yet all the atypicals have complex binding profiles and affect multiple 
neurotransmitter systems, which may contribute to their low propensity to induce 
EPS. On the other hand, no successful antipsychotic drugs have been made that are 
effective with out either D2 antagonism or partial agonism in the case of aripiprazole, 
suggesting that D2 receptor interaction is most important for antipsychotic treatment. 
 An experiment comparing pKi values of 13 typical and 7 atypical 
antipsychotic showed that atypical could be distinguished from typical drugs based on 
a lower affinity for the D2 receptor and higher affinity for 5-HT2 receptors (59). That 
is typical and atypical drugs formed into group based off their 5-HT2/D2 affinity 
ratios. This 1989 study included clozapine, and several drugs that to this date are not 
approved for the treatment of schizophrenia in the United States, such as ritanserin, 
SCH 23390, and zotepine (59).  Interestingly, all subsequently approved atypical 
antipsychotics have a higher affinity for 5-HT2A than D2 receptors. This hypothesis is 
based on a correlation found in this receptor affinity study, namely that compounds 
found to have higher affinities for the 5-HT2 receptor than D2 tend not to induce EPS 
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in humans and animals. To the best of my knowledge no direct and solid evidence has 
conclusively demonstrated an interaction of antipsychotics with serotonin receptors is 
the only property of the atypicals that reduces the likelihood of EPS. Furthermore, 
anticholinergics compounds, such as Trihexyphenidyl, have been used with some 
success to treat EPS suggesting that EPS involve multiple neurotransmitter systems. 
Clozapine and olanzapine have substantial muscarnic antagonist activity, yet research 
I have done has shown that olanzapine frequently induces catalepsy, which is a 
laboratory model of EPS. Since atypicals interact at a number of other receptor sites 
that may help reduce EPS liability, the definition of atypicality remains the term used 
to group clinically similar yet chemically diverse group of compounds.  Since the 
initial publication of this report in 1989 (59), it has been discovered that there are 
several 5-HT2 receptor subtypes, and isoforms of the D2 receptor raising questions 
about the validity of the 1989 results, because of the discovery of increased neuro-
complexity.   
 
Atypical Antipsychotics Pharmacology 
 
Clozapine is the only drug that is currently approved for treatment resistant 
schizophrenia, yet it is not clear what pharmacological properties are responsible for 
its superior efficacy. Clozapine, a dibenzodiazepine, is a mixed guanine nucleotide 
binding protein coupled receptor (GPCR) antagonist that binds to many 
dopaminergic, serotonergic, adrenergic, and muscarinic acetylcholine receptors. 
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Clozapines’ major metabolite N-desmethylclozapine is pharmacologically active with 
antipsychotic efficacy (80). Clozapine like all of the FDA approved atypical 
antipsychotics has a high 5HT2A/D2 binding affinity ratio, but also binds a number of 
other receptors including 5HT2C, D1, D3, and D4 receptors.  The search for the reasons 
why clozapine has superior efficacy had led researchers to look at individual receptor 
pharmacology in attempt to pinpoint both therapeutic effects as well as side effects. 
Clozapine has a higher affinity for the D1 receptor than D2 receptors (28), D1 
receptors are the main dopamine receptors in the prefrontal cortex and antagonism of 
these receptors is believed to be involved in improving negative (29) and cognitive 
(30) symptoms of schizophrenia. Interestingly, other atypical antipsychotics lack an 
appreciable affinity for D1 receptor, making D1 receptor antagonism a possible source 
of clozapine’s superior efficacy (31), yet selective D1 receptor antagonists lack 
antipsychotic properties (32,33). Clozapine also has a higher affinity for D4 receptors 
than D2, and antagonism of D4 receptors results in increased dopamine release in the 
basal ganglia and prefrontal cortex that may in part explain clozapine’s low 
propensity to induce EPS and the improved capacity to treat cognitive symptoms 
(34). Interestingly, D4 receptors are also overexpressed in the schizophrenia patient 
(35,36), yet selective D4 antagonists have had had little success as antipsychotics 
(37). 
Risperidone, a benisoxazole derivative was the first atypical antipsychotic 
marketed after clozapine. The major metabolite of risperidone is 9-OH- risperidone is 
an active metabolite with similar efficacy to the parent drug (79).  Risperidone also 
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bind 5HT2A and D2 receptors with high affinity, but has very little cholinergic 
blockade (38,39). Risperidone also antagonizes α1 and α2 adrenergic receptors, but 
with low affinity (79).  Risperidone is also a low affinity H1 receptor antagonist (79). 
Olanzapine, a thienobenzodiazepine, has a binding profile similar to clozapine 
although the affinities of olanzapine at its receptors sites are different from those of 
clozapine. For example, olazapine has a higher affinity at D1 and D2 receptors , while 
clozapine has a slightly higher affinity at D4 receptors (20). Olanzapine has a high 
binding affinity at  D1, D2, D4, D3, 5-HT2A, 5HT2C,  H1, α1 adrenergic, muscarinic M1-
5 receptors, and low affinity at α2, GABAA, and 5HT1 and β adrenergic receptors (20). 
In placebo-controlled studies, clinically significant alanine transferase (ALT) 
elevation of greater than three times the upper limit of the normal range was observed 
in 2% of patients taking olanzapine. Also, during pre-marketing studies, the incidence 
of ALT elevations was 2%, but this was not associated with jaundice or other 
symptoms attributable to liver impairment. Transient increases may be seen but 
usually normalize with olanzapine continuation (23). 
Ziprasidone has a binding affinity ratio of 11:1 for 5-HT2A/D2. Ziprasidone 
also binds with relatively high affinity for 5-HT2C, 5-HT1D, α1 adrenergic and D1 
receptors (21).  Ziprasidone has the highest 5-HT2A/D2 affinity ratio, and the highest 
5-HT2C/D2 ratio of all of the atypicals (71).  Due to high affinity for 5-HT2C receptors 
low does of ziprasidone result in substantial 5-HT2C antagonism without appreciable 
D2 antagonism that can result in dysphoria, hypomania, and panic without 
antipsychotic action (71).  These effects have been made apparent by the tendency of 
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clinicians to prescribe doses too small for effective treatment. Ziprasidone is also 
unique because it has the highest 5HT1A/D2 affinity ratio, and occupies this receptor 
to a greater extent than any approved antipsychotic drug.  Another unique feature of 
ziprasidone is its potent 5-HT1D antagonism , and it has been suggested that this 
action helps improve the mood of the schizophrenic patient because blockade of this 
receptor disinhibts serotonin release.  In addition ziprasidone is a reuptake inhibitor of 
serotonin, dopamine and norepinephrine.  Ziprasidone lacks M1, α1, and H1 activity 
seen in several other atypical antipsychotics such as clozapine and olanzapine.   
Quetiapine is dibenzothiazepine derivative with very little tendency to induce 
EPS (93). Quetiapine has high affinity for 5-HT2A receptors and lower affinity for D2 
and D1 receptors. This drug has some affinity for α1, α2, and H1 receptors, and very 
little for muscarinic receptors (22, 93). Quetiapines’ EPS liability is similar to that of 
clozapine, but does have the tendency to induce tachycardia, orthostatic hypotension, 
and sedation. One reason why quetiapine has a low propensity to induce EPS is 
probably because it is selective for mesolimbic D2 receptors rather than nigrostriatal 
D2 receptors (93).   
 Aripiprazole was discovered in the early 1980s as an attempt to find an 
antipsychotic that would function both as an antagonist and an agonist at the D2 
receptor. Hence, aripiprazole is the first potent D2 partial agonist for the treatment of 
schizophrenia. In a hyperdopaminergic state, aripiprazole functions as an antagonist, 
while under conditions of hypodopaminergic activity, it functions more like an 
agonist. This novel mechanism of aripiprazole has earned it the title of dopamine 
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stabilizer. Interestingly aripiprazole occupies 95% of striatal D2-like receptors yet the 
incidence of EPS was no greater than placebo in clinical trials. Aripiprazole has a 
high affinity for D2, D3, and 5-HT2A (Ki values of 0.34, 1.7 and 3.4 nM respectively), 
moderate affinity for D4, 5-HT2C, 5-HT7, α1, and H1 receptors ( Ki of 44, 15, 39,57 
and 62 nM respectively) and also has a moderate affinity for the serotonin reuptake 
site. Aripiprazole also has high affinity for D3 receptors. It is a partial agonist at 5-
HT1A receptors and an antagonist at 5-HT2A receptors. Aripiprazole has a moderate 
affinity for α1 and H1 receptors with no appreciable affinity for the M1 receptor (23).  
 
Extrapyramidal Side Effects (EPS) 
 
Extrapyramidal side effects (EPS), including akathisia, dystonia, tardive 
dyskinesia, and pseudoparkinsonism, are the major adverse effects associated with 
traditional antipsychotic therapy, and are associated to a lesser extent with the second 
generation antipsychotics. These side effects are widely believed to be the result of 
dopamine antagonism in the nigrostriatal pathways. Akathisia is the most frequently 
occurring of these adverse effects. Approximately 50% of patients treated with 
traditional antipsychotics will experience a subjective feeling of mental restlessness 
accompanied by motor symptoms. Akathisia causes intense anxiety, an inability to 
relax, and motor symptoms such as pacing, rocking while sitting, marching in place, 
constant fidgeting, and purposeless stereotypic movements (53). 
Dystonia is an early onset EPS that includes involuntary contractions in 
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opposing flexor and extensor muscles resulting in abnormal postures. Symptoms of 
dystonia include tongue protrusion, laryngeal-pharyngeal constriction, oculogyric 
crises, torticollis, and strange positioning of limb and torso (53). Of these tongue 
protrusion and laryngeal-pharyngeal constriction may have effects on the rhythmic 
licking behavior of rats, providing one reason that licking dynamics should be 
examined as a model of EPS.  
 Tardive dyskinesia (TD) is a movement disorder characterized by abnormal 
choreiform (observable, rapid, purposeless, irregular and spontaneous movement) and 
athetoid (slow and irregular) movements occurring late in onset in relation to 
initiation of antipsychotic therapy. This adverse effect usually develops over several 
months or years but usually requires at least three months of neuroleptic treatment. 
Patients showing symptoms of TD often display hyperkinetic movements of the limbs 
and trunks, and orofacial movement disorder.  Orofacial motor side effects consist of 
repetitive hyperkinetic movements including chewing, protrusion of the tongue, 
vermicular movements of the tongue, side to side or rotary jaw movements, and lip 
smacking (54). Even though TD is a late onset symptom of antipsychotic treatment 
and atypicals rarely produce TD, sensitization to licking variables in rats may prove 
as a predictor of atypical induced TD, or other subtle late onset movement disorders 
not heretofore fully characterized. The estimated average prevalence is 20% with a 
range of 13-36%. The incidence of new cases per treatment year with conventional 
antipsychotics is approximately 5% (24).  
Neuroleptic induced Parkinsonism is named as such because of its similarities 
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to Parkinson’s disease. This is an early onset side effect that can occur shortly after 
administration. The motor symptoms of drug induced Parkinsonism include tremor, 
rigidity, and bradykinesia. Patients exhibiting Parkinsonism often have expression 
less face, decreased arm movements during walking, and impaired ability to initiate 
movement, and small handwriting.   
Clozapine is associated with little to no EPS and quetiapine has been found to 
have no greater rates of EPS than placebo. Olanzapine and risperidone can cause EPS 
in a dose related fashion, but less frequently than traditional antipsychotics. 
Risperidone treatment is associated with Parkinsonism rates similar to placebo in 
doses under 6mg/day. Doses higher than 6mg/day are associated with EPS rates of 
20% or greater. Parkinsonism with olanzapine is similar to placebo with doses up to 
10 mg/day. At higher doses the rates increases to 20%. Akathisia with olanzapine is 
significantly higher than placebo at doses greater than 10mg/day.  
 
The Hypoglossal Nucleus and Neural Control of the Tongue 
 
 Neural control of the tongue enables a range of oropharyngeal behaviors, 
including licking, mastication, swallowing, vocalization, breathing, and coughing. 
Several of these behaviors, including licking, are controlled by central pattern 
generators (CPG's) located in the medulla and pons of the brainstem. These pattern 
generators transform ascending and descending signals into rhythmic and patterned 
behaviors. Disease states such as SIDS, and sleep apnea, and drugs have motor effects 
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on the tongue, making the study of the hypoglossal nucleus and licking dynamics a 
clinically relevant pursuit.  
 The tongue is composed of eight uncompartmentalized interdigitated muscles 
capable of meeting the motor demands of a multitude of complex orolingual 
behaviors. The tongue has four extrinsic muscles the syloglossus, hypoglossus, 
genioglossus, and geniohyoid, and four intrinsic muscles the longitudinal, transverse, 
vertical, and superior. The  intrinsic muscles determine the shape of the tongue  and 
have no bony attachments, and extrinsic muscle have bony attachments capable of 
directing tongue protrusion and retrusion. The genioglossus and the geniohyoid are 
tongue protrusor muscles, and the syloglossus and hypoglossus are the tongue 
retrusor muscles (43,44). However, current knowledge states that co-contraction of 
both intrinsic and extrinsic muscle simultaneously results in tongue movements 
(40,41,42).  Tongue protrusion is predominantly mediated by the activity of the 
genioglossus in combination with the intrinsic vertical and transverse tongue muscles. 
Retrusion is mediated predominantly by contraction of the styloglossus and 
hypoglossus and intrinsic longitudinal muscles.  The diversity of tongue movements 
required for the continuum of oropharyngeal behaviors is reflected by the myotopic 
organization of hypoglossal (XII) motor nucleus. The extrinsic and intrinsic tongue 
muscles are innervated by the medial branch of the XII nerve, and the somata of 
protrusor motor neurons are located in the ventral compartment of the hypoglossal 
nucleus. In contrast the extrinsic and intrinsic retrusors are innervated by the lateral 
branch of the XII nerve and the cell bodies are located in the dorsal compartment of 
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the nucleus. In addition, a small population of interneurons are intermingled among 
the XII motorneurons providing more complexity to the hypoglossal nucleus. These 
intrannuclear interneurons make up about 5% of the neurons of the hypoglossal 
nucleus, and are mainly located in the dorsolateral, lateral, and ventral margins. The 
genioglossus muscle is believed to control airway patency and is the main tongue 
protrusor muscle that is innervated by the motor neurons of the hypoglossal nucleus. 
The motorneurons here are believed to be stimulated at least in part by serotonin (81, 
82) and norepinephrine (83,84). Receptor localization studies have shown the 
presence of high numbers of 5-HT2A receptors on hypoglossal motor neurons 
(85,86,87), further supporting this receptors role in the control of hypoglossal motor 
neurons.  
Therefore, I hypothesize that compounds with α1, α2, and 5-HT2A antagonism 
will substantially reduce licking rhythm and D2 antagonism will reduced motivational 
behavior (defined as engaging in licking). Furthermore, a neuroleptic influenced 
reduction in the number of licks is reflective potential catalepsy, a model of EPS, 
based of the fact that several olazapine injections induces catalepsy, an others resulted 
in two minute sessions with minimal number of licks. 
 
Pre-Clinical Behavioral Analysis and Neuroleptic Drugs  
 
Despite its tendency to induce agranulocytosis (75), clozapine is an effective 
drug for treatment-resistant schizophrenic patients (60); moreover, clozapine has a 
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low EPS liability (61, 62). The therapeutic success of clozapine has stimulated the 
search for clozapine-like drugs without leukocytopenic side effects. Preclinical 
behavioral research has had a prominent role in this effort (63, 64, 65, 66, 67, 68, 69, 
70), and the identification of behavioral bio-markers can aid in the identification of 
clozapine-like drugs. Within this context it has been reported that the dominant 
rhythm of oscillations in rats’ forelimb force was slowed by clozapine but not by 
haloperidol (76), a behavioral property distinguishing clozapine from the typical 
antipsychotic haloperidol. In a separate study, it was observed that another rhythmic 
behavior of rats, tongue movements made while licking water from a force sensing 
disc, was only slightly affected by haloperidol ( 77,78). Another study showed that 
only a chronic haloperidol regimen was capable of reducing  licking rhythm (74). 
Other research has shown that risperidone also slows licking rhythm in a similar 
fashion to clozapine (73). On the other hand, acute clozapine treatment was 
previously shown to induce a dose dependent reduction in licking rhythm (72). The 
data presented in this thesis, in addition to previous studies, show that clozapine has 
significant effects on several variables of tongue dynamics including peak force, 
number of licks, and rhythm.  
In addition to testing the above mentioned hypothesis this work had several 
other purposes, including comparison among the atypicals, and a comparison to 
similar research done with the typical neuroleptic haloperidol. One purpose of the 
present work was to compare the effects of clozapine on licking behavior to 
risperidone, olanzapine, aripiprazole, quetiapine fumarate, and olanzapine, and to 
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compare the effects of oral clozapine to previous reports. Accordingly rats were 
administered three or four acute doses of each of the atypical antipsychotic drugs 
(AADs) listed above, and the effects on licking behavior were characterized by 
measuring the rhythm of tongue (with Fourier methods), the peak force, and number 
of licks. A second purpose was to assess compare the potency of AAD induced motor 
effects and to compare them to previous data collected for haloperidol. A third 
purpose of this work  was to search for putative behavioral markers of atypicality 
using clozapine as a standard on the basis that clozapine is a drug of choice in 
treatment resistance schizophrenic patients. A fourth purpose was to assess the 
tolerance and/or sensitivity to the behavioral effects using a subchronic dosing 
regimen in order to assess any tolerance or sensitization effects that could be used to 
distinguish among AADs. Tolerance to such motor side effects could suggest a more 
effective drug particularly with respect to patient compliance.   Sensitization may be 
useful in predicting if a drug will be likely to induce worsening side effects.   
 
Material and Methods 
Acute regimen 
Nine male, Sprauge-Dawley rats (Harlan, Indianapolis, Ind.) served as 
subjects. Rats were maintained on a water restriction regimen of 10-15 minutes 
access 30 minutes after the 2 minute experimental session. This water restriction 
regimen allowed for adequate hydration as rats steadily gained 5-6 grams per week.  
The purpose of the water restriction was to obtain maximal motivation to lick water 
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during the 2 minute test period. Measurement of licking dynamics occurred between 
12 and 2 pm daily during the light portion of the light-dark cycle in the vivarium 
(lights on from 6 a.m. to 6 p.m.). At the time of experimental evaluation of the drugs 
effects on licking dynamics, rats averaged 225 grams in body weight and were about 
3 months old.   
 
Sub-chronic regimen 
 
Thirty four male, Sprauge-Dawley (Harlan, Indianapolis, Ind.) rats served as 
subjects. Rats were maintained on a water restriction regimen of 10-15 minutes 
access 30 minutes after the 2 minute experimental session for the same reasons 
described above for the acute experiments. Recording times, light cycle were the 
same as in the acute experiments. At the time of the evaluation of the drugs effects on 
licking dynamics, rats averaged 247 grams and were about three and a half months 
old. 
 
Apparatus 
 
The licking recording chamber has been described elsewhere in detail (78). A 
rodent operant chamber was modified so that the panel in which the lever was 
mounted was replaced with another panel containing a 6 cm x 6 cm opening at flour 
level. Covering this opening from the outside was a 3 cm deep transparent plastic 
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enclosure with a 12 mm diameter hole on the bottom of its surface. Lick force-time 
wave plots were recorded by attaching an 18 mm diameter lick disc to the shaft of a 
force transducer (Sensotec model 31a) (Figure 1). The surface of the lick disc was 
placed 1mm below the 12 mm diameter hole through which the rat extended its 
tongue. The plastic material through which the hole was cut was 1 mm thick making 
the lick disc 2 mm from the rats’ mouth. The larger the distance between the rats’ 
mouth and the force transducer, the lower the number of licks, the peak force, as well 
as the lick rhythm (figure 2). The force transducer was calibrated to measure force in 
units of 0.2 gram equivalent weight. A Labmaster interface recorded the force-time 
wave data at a sample rate of 100 per second via a 386 based computer.  Water (0.055 
ml) was delivered onto the lick disc by 5 gauge stainless steel tubing when the 
computer activated peristaltic pump connecting the water reservoir and the tubing to 
the lick disc. The computer program measured the number of licks and continuous 
force transducer output in real time. The force threshold for lick detection was 1.0 
gram, and the force criterion for programmed consequences was 4.0 g. The entire 2-
min session was stored in RAM and transferred to a hard disc at the end of each 
session for Fourier analysis, and other analyses. 
 
Procedure 
 
The rat training procedure was previously described (78). Water (0.100 ml), 
was placed onto the lick disc and naive rats were placed into the chamber for two 
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minutes until rats licked at least 400 times in a two minuet session three days in a 
row.  The emission of 12, 4 g licks resulted in the delivery of 0.055 ml of tap water 
onto the disk. Recording sessions lasted 120.32 seconds or about 2 min. Observation 
of the effects of acute oral clozapine (10.0 mg/kg, 5.0 mg/kg, 20.0 mg/kg), acute oral 
aripiprazole (6.0 mg/kg, 12.0 mg/kg, 18.0 mg/kg), acute oral risperidone (0.50 mg/kg 
0.25 mg/kg, 1.0 mg/kg, 2.0 mg/kg), acute oral ziprasidone (1.0 mg/kg, 0.50 mg/kg, 
2.0 mg/kg, 4,0 mg/kg) acute oral quetiapine fumarate (10.0 mg/kg, 5.0 mg/kg, 20.0 
mg/kg), and acute oral olanzapine (2.0 mg/kg, 1.0 mg/kg, 4.0 mg/kg) were 
administered in the dose order indicated in the parenthesis three days apart.  After two 
days of licking and no drug or vehicle treatment each rat served as its own control and 
received vehicle (Carboxymethylcellulose sodium salt) at 5 ml/kg the day before drug 
treatment. The additional doses of risperidone (2.0 mg/kg), and ziprasidone (4.0 
mg/kg) were added because the effects of these drugs on licking dynamics were 
present but small in the series of lower doses.  
In the subchronic  studies 10 rats were given vehicle (5 ml/kg), 8 rats were 
given oral clozapine (20.0 mg/kg), 8 rats were given oral risperidone (2.0 mg/kg), and 
8 rats were given oral olanzapine (4.0 mg/kg) twice a day 12 hours apart. Drugs were 
administered at 12 noon and 12 midnight seven days a week, and the experimental 
session was between 12-2 pm seven days a week.   
 
Drugs 
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All drugs were obtained in tablet form from the pharmaceutical companies 
listed below and were crushed and placed in a constantly stirred suspension of 
carboxymethylcellulose sodium salt immediately prior to administration. Clozapine 
25 mg (TEVA), aripiprazole 30 mg (Bristol-Myers Suibb), risperidone 2mg and 4 mg 
(Janssen), ziprasidone 20 mg (Pfizer), quetiapine fumarate 25 mg (AstraZeneca), and 
Olanzapine 10 mg (Eli Lilly).  Vehicle and drug were administrated at approximately 
equal volumes. Oral administration of each drug or vehicle was given 45 min before 
the beginning of each 2 min session. 
 
Dependent Variables 
 
As rats lick the force transducing lick disc, force measurements are recorded 
in real time by a computer for subsequent quantitative analysis. Shown below is an 
example force-time wave plot (Figure-3) depicting variables generated by the lick-
force-rhythm test for quantitative analysis. The number of licks is a behavioral 
variable that can provide insight into the effects of AADs on motivation that should 
be maximal due to the water restriction regimen. Peak force can reveal the effects of 
atypical antipsychotics on the neuromuscular control of tongue and the effects of 
AADs on hypoglossal motor neuron output. The lick rhythm reveals the effects of 
AADs on the established dominate rhythmic frequency of licking in Sprague Dawley 
rats of 6 Hz.  Lick duration, inter-lick, and period are other variables available for 
analysis from the lick-force-rhythm test for analysis. The duration of the lick is the 
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width of the peak generated by the force of one lick and the inter-lick interval is the 
time elapsed between licks. The period is defined as the sum of the lick duration and 
inter-lick interval and provides complimentary data to the lick rhythm. 
 
Quantitative Analysis 
 
The effects of acute and subchronic doses were measured in terms of the 
number of licks in 2 minutes and the dominant rhythm of licking was measured in Hz 
(cycles/sec) by Fourier spectral analysis techniques described previously (77, 78). 
The dominant rhythm of lick oscillation was taken as the spectral peak in the 3.5-6.5-
Hz region of the spectrum computed by Fourier methods for each rat each session. 
With these methods the dominant lick rhythm is a measure of periodic tendency of 
the licking behavior; therefore, the rhythm of the oscillatory process of licking can be 
largely independent of the number of licks. For example, two rats could have nearly 
the same dominant licking rhythms, even though one of them stops licking halfway 
through the session and thus emits 50% fewer licks than the other rat. Dose effect 
one-way analyses of variance (ANOVAs) were used for all acute dosing experiments 
and linear trend tests were used to analyze subchronic data. Data were expressed as a 
proportion of vehicle control, where the vehicle performance was for each subject an 
average of vehicle sessions.   
 
 
 
 
 
23 
Results 
 
In Figure-4 is a sample of an actual force-time wave plots for the same rat 
when given saline vehicle (top two rows) and an acute oral dose of 20.0 mg/kg of 
clozapine (bottom two rows).  All data discussed is either directly obtained from 
force-time wave plots or derived from force-time wave plots, in the case of lick 
rhythm by Fourier analysis.  All of the six atypical antipsychotic drugs approved for 
the treatment of schizophrenia with the exception of aripiprazole had marked effects 
on licking dynamics when compared to vehicle controls.  The effects of Aripiprazole 
on licking dynamics were either statistically insignificant or slight. This is probably 
due to Aripiprazole’s partial agonism of D2 receptors and its dopamine stabilizing 
activity, which is unique among the compounds studied. In the acute studies each rat 
served as its own control and was administered saline vehicle the day before drug 
administration. The data from the vehicle days were averaged for comparison to data 
from days in which drugs were administered, and all data was analyzed by one way 
ANOVA.  All mean, SEM, and one way ANOVA data of acute oral AAD 
administration for the peak force of licking, the number of licks, and lick rhythm are 
presented in tables 1, 2, and 3. Clozapine dose dependently reduced the peak force, 
the number of licks, and lick rhythm in a two minute session.  Aripiprazole showed 
no statistically significant effect on the average number of licks, but had slight 
statistically significant effects on the peak force, and lick rhythm.  Aripiprazole was 
the only compound studied that had no significant effect on the number of licks. 
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Clozapine risperidone, ziprasidone, quetiapine fumarate, and olanzapine, all 
significantly reduced the number of licks in the two minute experimental session 
(figure-3, and figure -6, tables 1-3).  
 With respect to licking rhythm, all six AADs had a significant effect. Data 
collected on days when no vehicle or drug was administered showed that the 
dominant lick rhythm for Sprague Dawley rats is about 6.0 Hz with no statistically 
significant variation (data not shown), and all vehicle data are consistent with that 
finding. The 20.0 mg/kg dose of clozapine had the largest effect on lick rhythm of all 
compound and doses in this study. The effects of aripiprazole on lick rhythm were 
significant from vehicle but each increasing the dose had no additional significant 
decrease of rhythm. Risperidone was the most potent, affecting lick rhythm at doses 
substantially lower that all drugs studied. Risperidone effect on rhythm at 2.0 mg/kg 
was close to the effects of clozapine at 20.0 mg/kg. Ziprasidone also has a very potent 
effect on lick rhythm at low doses. Olanzapine at 4.0 mg/kg was comparable to 20.0 
mg/kg of clozapine but was much more potent in causing an effect. Aripiprazole had 
only minor effects on licking rhythm, as each dose of aripiprazole was statistically 
significant from vehicle, but no dose (6.0 mg/kg, 12.0 mg/kg, or 18.0 mg/kg) was 
significant from each other. That is no dose response was observed, possibly due to 
its low affinity for the α1 adrenergic receptor, and low occupancy at 5-HT2A seen at 
therapeutically relevant doses of aripiprazole (23), antagonism of which is believed to 
slow hypoglossal motor neuron basal activity (86). Risperidone the most likely of the 
atypicals to induce extrapyramidal symptoms was most potent at all motor-behavioral 
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variables analyzed (89,90). 
 All six AADs had significant effects on the peak force of licking with varying 
degrees of potency. The highest dose of clozapine had a large effect on the peak force 
of licking but the potency of the effect was low at 20.0 mg/kg clozapine produced an 
effect similar to 2.0 mg/kg of risperidone, 4.0 mg/kg of ziprasidone, and 4.0 mg/kg of 
olanzapine.  Again, the effects of aripiprazole were slight compared to most 
compounds tested. Risperidone was the most potent at reducing the peak force of 
licking producing a large effect at just 2.0 mg/kg. Ziprasidone also had a very potent 
effect on the peak force. Quetiapine had a significant but not very potent dose 
dependent reduction of the peak force. Olanzapine, risperidone, and ziprasidone 
making up the high potency group at all acute licking variables analyzed.  Data for all 
six drugs are shown as proportion of control as well as in graphs not including the 
control values for better visualization (figure 3-6). In order to allow for potency 
comparison of the effects of all six AADs on licking dynamics all drugs were placed 
on the same graph by using a Log10 of dose scale. 
 Subchronic experiments were done using clozapine, risperidone, olanzapine in 
order to assess whether tolerance or sensitization to effects of AADs could be 
detected. Altered lick dynamics can be viewed from several different perspectives. It 
can be viewed as a model of EPS, a bio-behavioral marker for clozapine-like drugs or 
as a side effect of atypical antipsychotic drugs. Tolerance to the effects of AADs on 
licking dynamics can be viewed as a predictor to whether or not orolingual side 
effects will ease with time. The pharmacology of clozapine is so complicated that the 
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Lick-force-rhythm test could serve as an early screen for putative antipsychotic drugs. 
As a model of EPS it may be predictive of orolingual effects of neuroleptic 
Parkinsonism, or in the case of sensitization of orolingual motors effect associated 
with late onset EPS such as Tardive Dyskinesia.  
 Clozapine [F(1,13)= 39.775, p< 0.0001] significantly reduced the number of 
licks each of the ten days with no trend towards tolerance or sensitivity as determined 
by polynomial test of order 1 [F(1,13)= 0.876, p<0.366]. Risperidone also reduced the 
number of licks each of the ten days [F(1,14)= 21.877, p< 0.0001], again with no 
trend toward tolerance or sensitization [F(1,14)= 0.717, p<0.411]. Olanzapine also 
significantly reduced the number of licks [F(1,10)= 45.438, p< 0.0001] and displayed 
a sensitization effect [F(1,10)= 4.112, p<0.0001]. Olanzapine frequently induced a 
cataleptic state in which animals did not lick or move during their two minute session. 
Cataleptic episodes increased later in the ten day dosing regimen.  
 Clozapine reduced the lick rhythm each of the tend days [F(1,13)= 8.886, p< 
0.012] with no trend toward tolerance or sensitization [F(1,13)= 0.081, p<0.780]   
Risperidone reduced the lick rhythm each of the ten day [F(1,14)= 15.965, p< 0.0001] 
with no trend towards tolerance or sensitization [F(1,14)= 0.475, p<0.503]. 
Olanzapine reduced the licking rhythm each of the ten days [F(1,9)= 19.220, p< 
0.002] and showed no significant trend towards sensitization [F(1,9)= .089, p< 
0.769].  
 Clozapine effected the peak force of licking each of the ten days 
[F(1,13)=12.337, p<0.003] with no significant trend toward tolerance or sensitization 
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[F(1,13)=0.321, p<0.579].  Risperidone has a significant effect on the peak force of 
licking [F(1,14)=10.558, p<0.005] with a significant trend towards sensitization 
[F(1,14)=5.334, p<0.034]. Olanzapine had a significant effect on the peak force of 
licking [F(1,9)=8.219, p<0.011] with no significant trend towards tolerance or 
sensitization [F(1,9)=2.424, p<0.139]. Risperidone displayed a trend towards 
sensitization of peak force of licking suggesting its potential for orofacial EPS that 
may worsen with a more chronic dosing regimen.   
 
Conclusion and Discussion  
 
 Licking dynamics serves as a model for EPS induced by atypical 
antipsychotics. Both tardive dyskinesia, dystonias and neuroleptic induced 
Parkinsonism have orofacial and tongue motor side effects, thus irregularities in 
tongue movements can be used to model the likelihood of neuroleptic agents to 
induce EPS. Tardive dyskinesia is a late onset side effect, whereas dystonias, and 
Parkinsonism is an early onset side effect. The acute and subchronic alterations in 
licking dynamics described here may be more suggestive of Parkinsonism and early 
onset EPS than Tardive dyskinesia and later onset EPS.  
Previous work with the effects of clozapine on licking dynamics showed 
similar dose dependent decreases in licking rhythm and number of licks with acute 
dosing regimens (72). Subchronic investigations revealed a tolerance to the disruptive 
effects on the number of licks but not to clozapines’ rhythm slowing effects (72). The 
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current study differed in that no tolerance to clozapines’ disruptive effects on number 
of licks was observed. This discrepancy could have been due to the fact that oral 
doses were administered in this study instead of the intraperitoneal route of 
administration in the previous study, or due to differences in doses. Subchronic 
intraperitoneal doses in the previous study were administered at 1.5, 4.5, and 6.0 
mg/kg once a day, whereas subchronic doses in this experiment were given orally at 
20.0 mg/kg twice daily and this may account for observed differences. Thus, it is 
possible that even after first pass metabolism rats in this study were exposed to more 
drug (particularly with the two doses per day), and tolerance to the disruption of the 
number of licks may have developed if the experiment had included more days. Both 
studies confirmed that no tolerance to the rhythm slowing effects of clozapine.  Other 
work has demonstrated that risperidone also dose dependently reduced the lick 
rhythm in a similar fashion to clozapine (91).     
Olanzapine has also been shown to have clozapine-like effect on the peak 
force, rhythm and number of licks (92). An in depth analysis and comparison of the 
effects of all six atypical antipsychotics on licking dynamics has not been done, and 
this research allowed a comparison of available AADs with clozapine. Clozapine is 
viewed  as a reference compound in which to compare the rest of the AADs, because 
its effectiveness has yet to be surpassed and is the only AAD currently indicated for 
the treatment of refractory schizophrenic patients. Similarities with clozapine may 
predict which new agents will be clozapine-like, and effective antipsychotic 
compounds warranting future investigation. The high potency group contained the 
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most likely AADs (risperidone, olanzapine) to induce EPS, whereas the low potency 
group contained those least likely to induce EPS (clozapine, quetiapine, and 
aripiprazole) (89).  In this way the lick-force-rhythm test appeared to identify 
clozapine like drugs with respect to the potential to induce EPS, and may be useful as 
a bio-behavioral screen for putative clozapine-like antipsychotics.   
Upon comparison of the number of licks, peak force and rhythm of the six 
atypical antipsychotics after acute exposure, it becomes apparent that there are at least 
two potency groups. Risperidone, ziprasidone, and olanzapine make up an easily 
distinguishable high potency group in which low doses have large effects on all three 
variables. Clozapine, aripiprazole, and quetiapine fumarate make up a low potency 
group, but even at these higher doses only clozapine produced effects comparable to 
the maximal effects observed with risperidone, ziprasidone, and olanzapine. 
Aripiprazoles’ effects were particularly slight with no effect on the number of licks 
and only a slight effect on the peak force and lick rhythm. Aripiprazole has dopamine 
stabilizing activity functioning as an agonist in a hypodopaminergic state and an 
antagonist in a hyperdopaminergic state (23), and this may explain its only slight 
effects on licking dynamics. While quetiapines’ effects were statistically significant 
for all three variables, the effects were not large, which is consistent with its low 
propensity to induce EPS (93).    
 Subchronic dosing regimens were administered in order to determine if 
tolerance or sensitization to these disruptive effects on licking dynamics occurred 
over time. Clozapine, olanzapine, and risperidone were selected for subchronic 
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studies for several reasons. One reason is that risperidone has very high affinity for 5-
HT2A receptors, olanzapine has intermediate affinity, and clozapine has a lower 
affinity for this receptor.  This would allow for the investigation of a range affinities 
for 5-HT2A receptors which are hypothesized to slow hypoglossal motor neuron 
control of the genioglossus muscle. Also these drugs represented a low (clozapine), 
medium (olanzapine) and high potency (risperidone) sample of the six drugs tested 
acutely. Additionally, the maximum effects of these compounds on licking dynamics 
were large allowing lots of room for quantifiable tolerance even though no tolerance 
was observed. All three compounds had a significant effect on the number of licks, 
peak force, and lick rhythm with no trend towards tolerance or sensitization with two 
exceptions. First, olazapine showed sensitization to the disruptive effects to the 
number of licks. The number of lick diminished over ten days, in fact, several rats did 
not lick and appeared cataleptic. Upon experimentation with olanzapine it was 
observed that rats given higher doses of olanzapine assumed hunched postures, with 
an inability to control their front limbs enough for simple movement, and were 
generally flaccid when held. Furthermore, rats became unresponsive to stimuli and 
ceased engagement in the learned task of licking from the lick disc. This type of 
cataleptic behavior is suggestive of olanzapine induced EPS-like syndrome only 
observed with olanzapine in these studies.   All olanzapine rats that did not lick at all 
were excluded from the data analysis to prevent skewing data concerning peak force 
and rhythm, and had they been included the trend towards sensitization to the 
disruptive effect to the number of licks would have been more marked. Second, the 
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peak force of licking for the rats administered risperidone showed sensitization, that 
is a trend over the ten days to a lower peak force of licking. Risperidone and 
olanzapine have  been shown have a higher EPS liability than other AADs and these 
results towards sensitization agree with that. 
 Previous work investigating the effects of haloperidol on licking dynamics 
showed that acute haloperidol did not have a significant effect on lick rhythm, but did 
have disruptive effects on the number of licks and peak force.  Therefore, it seems 
likely that compounds with α1, α2, and 5-HT2A antagonism will substantially reduce 
licking rhythm, and compounds with D2 antagonism will reduced the motivational 
behavior to lick.  The alteration of licking dynamics may serve as a useful model in 
the screening of clozapine-like drugs that could be potentially used as antipsychotic 
drugs. Furthermore, a neuroleptic influenced reduction in the number of licks is 
reflective of potential catalepsy, a model of EPS, based on the fact that several 
olazapine injections induced catalepsy, an other olanzapine injections resulted in two 
minute sessions with minimal number of licks (77, 92).  Thus, licking dynamics may 
be predictive of EPS liabilities of potential antipsychotic compounds.  
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The Effects of Acute AADS on the Peak Force of Licking (0.2 g) 
 
 
 
 
 
 
 
 
 
 
Drug 
 
Vehicle  Dose 1 Dose 2 Dose 3 Dose 4 One Way 
ANOVA 
5.0 
mg/kg 
10.0 
mg/kg 
20.0 
mg/kg 
Clozapine 
 
51.500 + 
1.829 
53.778 + 
4.421 
41.883 + 
3.745 
27.889 + 
2.220 
 [F(3,24)=16.838, 
p<0.001] 
6.0 
mg/kg 
12.0 
mg/kg 
18.0 
mg/kg 
Aripiprazole 
 
47.630 + 
2.975 
43.000 + 
3.636 
40.111 + 
3.745 
39.667 + 
3.100 
 [F(3,24)=4.183, 
p<0.016] 
0.25 
mg/kg 
0.5 
mg/kg 
1.0 
mg/kg 
2.0 
mg/kg 
Risperidone 
 
47.056 +  
3.666 
43.278 + 
4.242 
43.000 + 
2.769 
36.222 + 
3.459 
28.444 + 
2.698 
[F(4,32)=19.132, 
p<0.0001] 
 
0.5 
mg/kg 
1.0 
mg/kg 
2.0 
mg/kg 
4.0 
mg/kg 
Ziprasidone 
 
47.569 + 
3.836 
43.889 + 
2.685 
39.889 + 
3.490 
33.778 + 
2.886 
28.444 + 
2.352 
[F(4,32)=33.649, 
p<0.0001] 
5.0 
mg/kg 
10.0 
mg/kg 
20.0 
mg/kg 
Quetiapine 
 
42.185+ 
4.716 
39.111 + 
4.008 
38.889 + 
4.560 
32.333+ 
1.929 
 [F(3,24)=6.359, 
p<0.003] 
1.0 
mg/kg 
2.0 
mg/kg 
4.0 
mg/kg 
Olanzapine 
 
43.019+ 
3.343 
39.444 + 
3.583 
32.556 + 
2.678 
28.667 + 
2.427 
 [F(3,24)=27.117, 
p<0.0001] 
Table 1- Mean and standard error of the mean values (SEM) of the peak force of 
licking for acute oral dosing of clozapine, aripiprazole, risperidone, ziprasidone, 
quetiapine, and olanzapine. 
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The Effects of Acute AADS on the Number of Licks 
 
 
 
 
 
 
 
 
 
Drug 
 
Vehicle  Dose 1 Dose 2 Dose 3 Dose 4 One Way 
ANOVA 
5.0 
mg/kg 
10.0 
mg/kg 
20.0 
mg/kg 
Clozapine 
 
647.185 
+ 22.473 
667.111 
+ 15.515 
498.667 
+ 64.477 
438.000 
+ 40.744 
 [F(3,24)=6.715,  
p<0.002] 
6.0 
mg/kg 
12.0 
mg/kg 
18.0 
mg/kg 
Aripiprazole 
 
654.926  
+ 19.222 
667.111 
+ 15.515 
626.778 
+ 22.515 
608.333 
+ 17.494 
 [F(3,24)=1.954,  
p<0.148] 
 
0.25 
mg/kg 
0.5 
mg/kg 
1.0 
mg/kg 
2.0 
mg/kg 
Risperidone 
 
710.194  
+ 13.648 
692.333 
+ 10.919 
683.000 
+ 17.912 
656.333 
+ 18.575 
553.778 
+ 21.216 
[F(4,32)=19.860,  
p<0.0001] 
0.5 
mg/kg 
1.0 
mg/kg 
2.0 
mg/kg 
4.0 
mg/kg 
Ziprasidone 
 
714.278 
+ 13.133 
696.556  
+ 21.868 
688.111 
+ 16.248 
661.889 
+ 25.313 
559.778 
+ 28.638 
[F=(4,32)21.146,  
p<0.0001] 
5.0 
mg/kg 
10.0 
mg/kg 
20.0 
mg/kg 
Quetiapine 
 
726.185+ 
13.800 
711.222 
+ 14.016 
704.556 
+ 14.998 
667.444 
+ 22.703 
 [F=(3,24)14.204,  
p<0.0001] 
1.0 
mg/kg 
2.0 
mg/kg 
4.0 
mg/kg 
Olanzapine 
 
715.185 
+ 14.068 
712.889 
+ 13.752 
664.667 
+ 16.686 
437.556 
+ 64.437 
 [F(3,24)=14.286,  
p<0.0001] 
Table 2- Mean and standard error of the mean values (SEM) of the number of licks 
for acute oral dosing of clozapine, aripiprazole, risperidone, ziprasidone, quetiapine, 
and olanzapine. 
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The Effects of Acute AADS on the Lick Rhythm (Hz) 
 
Drug 
 
Vehicle  Dose 1 Dose 2 Dose 3 Dose 4 One Way 
ANOVA 
5.0 
mg/kg 
10.0 
mg/kg 
20.0 
mg/kg 
Clozapine 
 
5.925 + 
0.078 
5.815 + 
0.090 
5.632 + 
0.119 
5.135 + 
0.096 
 [F(3,24)=15.492,  
p<0.0001] 
6.0 
mg/kg 
12.0 
mg/kg 
18.0 
mg/kg 
Aripiprazole 
 
6.041 + 
0.084 
5.827 + 
0.054 
5.689 + 
0.109 
5.800 + 
0.096 
 [F(3.24)=12.664, 
p<0.0001] 
0.25 
mg/kg 
0.5 
mg/kg 
1.0 
mg/kg 
2.0 
mg/kg 
Risperidone 
 
6.086 + 
0.087 
5.962 
+0.089 
5.787 
+0.111 
5.735 + 
0.124 
5.418 + 
0.108 
[F(4,32)=32.643, 
p<0.0001] 
0.5 
mg/kg 
1.0 
mg/kg 
2.0 
mg/kg 
4.0 
mg/kg 
Ziprasidone 
 
6.116 + 
0.086 
5.972 + 
0.098 
5.895 + 
0.098 
5.871 + 
0.116 
5.635 + 
0.125 
[F(4,32)=12.470, 
p<0.0001] 
5.0 
mg/kg 
10.0 
mg/kg 
20.0 
mg/kg 
Quetiapine 
 
6.191+ 
0.084 
6.072+ 
0.087 
6.079 + 
0.080 
5.832+ 
0.144 
 [F(3,24)=10.403, 
p<0.0001] 
1.0 
mg/kg 
2.0 
mg/kg 
4.0 
mg/kg 
Olanzapine 
 
6.136+ 
0.086 
6.048+ 
.087 
5.95+ 
0.093 
5.337 + 
0.078 
 [F(3,24)=41.494, 
p<0.001] 
Table 3- Mean and standard error of the mean values (SEM) of the lick rhythm for 
acute oral dosing of clozapine, aripiprazole, risperidone, ziprasidone, quetiapine, and 
olanzapine. 
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Figure 1.  Photograph of a hardware ensemble for measuring tongue force during 
licking of liquids by rats or mice.  Liquids to be ingested are carried to the lick disk 
by a computer-controlled peristaltic pump. The lick disk through which the liquid 
emerges for consumption is 18 mm in diameter. Rats or mice access the disk by 
protruding their tongues through a 12-mm-diameter hole (88). 
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Figure 2.  Effects on lick measures for three different distances between the rats’ 
muzzles and the liquid orifice.    Mean peak force (expressed in gram-equivalent 
forces), lick  rhythm (Hz), and number of licks each significantly decreased as a 
function distance.  Data were taken from Table 2, pg 83 in Fowler, S.C., McKerchar, 
T.L., Zarcone, T.J. (2005). Response dynamics: Measurement of the force and rhythm 
of motor responses in laboratory animals. In M. LeDoux (Ed.) Animal models of 
movement disorders. San Diego, CA: Academic Press, 73-100. 
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Figure 3 Force Time wave plot- Each lick is represented by a peak whose peak 
force is its apex, the duration of the lick is the base of the peak for any given lick. The 
inter lick interval is the time between the licking peaks. The period is defined as the 
inter-lick interval summed with the duration of the lick.  Using Fourier methods 
licking rhythm (Hz) can be calculated. The dominant licking rhythm of a Sprague 
Dawley rat either untreated or treated with vehicle is approximately 6 Hz.  
 
 
 
 
 
 
 
 
 
 
Peak force 
Duration Period Force threshold 
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Saline injection, Rhythm=5.85 Hz
12 gram-force
1 s
Clozapine 20.0 mg/kg injection, Rhythm=5.53 Hz
 
 
 
 
Figure 4  Effects of saline (top two rows) and the atypical antipsychotic drug, 
clozapine (bottom two rows), on lick-force-time waveforms generated by a rat licking 
water from the disk shown in Fig. 1  Note the diminution in peak force in the lower 
set of graphs, as well as the appearance of long inter-lick intervals.  An illustrative 
example of a “notched” lick waveform induced by 20 mg/kg clozapine is indicated by 
the ellipse. The notched lick wave form represents a lack of control of the tongue 
under the influence of clozapine.  
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Figure 5- Shows the acute effects of AADs on the number of licks in a two min 
session. Risperidone in orange was the most potent at affecting the number of licks at 
the lowest doses (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, and 2.0 mg/kg) 
[F(4,32)=19.860,  p<0.0001]., and ziprasidone (purple, 0.5 mg/kg, 1.0 mg/kg, 2.0 
mg/kg, and 4.0 mg/kg) [F=(4,32)21.146,  p<0.0001], and olanzapine (black, 1.0 
mg/kg, 2.0 mg/kg, and 4.0 mg/kg) [F(3,24)=14.286,  p<0.0001], also showed high 
potency effects. The lower potency group consisting of clozapine (red 5.0 mg/kg, 
10.0 mg/kg, 20.0 mg/kg) [F(3,24)=6.715,  p<0.002], aripiprazole (blue, 6.0 mg/kg, 
12.0 mg/kg, and 18.0 mg/kg), which has no significant effects on the number of licks 
[F(3,24)=1.954,  p<0.148], and quetiapine fumarate (green, 5.0 mg/kg, 10.0 mg/kg, 
20.0 mg/kg) [F=(3,24)14.204,  p<0.0001],  displayed minimal effects or effects at 
much higher doses doses that risperidone, ziprasidone, and olanzapine. Higher doses, 
particularly of olanzapine and clozapine show the most variability from rat to rat as 
indicated by the SEM bars.  
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Figure 6- Shows the acute  effects of AADs on lick rhythm during the two minute 
sessions. Risperidone again was the most potent at affecting licking rhythm. Lick 
rhythm was also more or less divided into low and high potency groups, once again 
risperidone (orange) [F(4,32)=32.643, p<0.0001] was the most potent at the slowing 
of the lick rhythm. Also in the high potency group was ziprasidone (purple) [F(4,32)= 
12.470, p<0.0001], and olanzapine (black) [F(3,24)=41.494, p<0.001]. The lower 
potency group is comprised of clozapine (red) [F(3,24)=15.492,  p<0.0001]., 
Aripiprazole ( blue) [F(3.24)=12.664, p<0.0001] , and quetiapine (in green) 
[F(3,24)=10.403, p<0.0001]. Compared to the rest of the compounds the effects of 
aripiprazole and quetiapine are small and not very potent.  
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Figure 7-Shows the effects of acute AAD doses on the peak force of licking. Potency 
was again divided into two groups, a high potency group consisting of risperidone 
(orange) [F(4,32)=19.132, p<0.0001], ziprasidone (purple) [F(4,32)=33.649, 
p<0.0001], and olanzapine (black) [F(3,24)=27.117, p<0.0001]. The low potency 
group consisted of clozapine (red) [F(3,24)=16.838, p<0.001], aripiprazole (blue) 
[F(3,24)=4.183, p<0.016], and quetiapine (green) [F(3,24)=6.359, p<0.003]. 
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Figure 8- The Acute effect of AADs on the number of licks, licking rhythm and peak 
force of licking represented as a proportion of control. Risperidone (orange), 
ziprasidone (purple), olanzapine (black),  clozapine (red), aripiprazole (blue), and 
quetiapine (green).       
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Figure-9 The effects of subchronic clozapine, risperidone, and olanzapine on the 
number of licks. Clozapine (red triangles, upper graph) given at 20.0 mg/kg twice 
daily had a significant effect on the number of licks each of the ten days [F(1,13)= 
39.775, p< 0.0001], and displayed no trend towards tolerance or sensitization 
[F(1,13)= 0.876, p<0.366] (vehicle controls blue circles, upper graph). Risperidone 
(orange triangles, middle graph) also had a significant effect on the number of lick 
each of the ten days  [F(1,14)= 21.877, p< 0.0001], with no significant trend towards 
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tolerance or sensitization [F(1,14)= 0.717, p<0.411] (vehicle controls blue circles, 
middle graph). Olanzapine (black triangles, lower graph)  had a significant effect on 
the number of licks each of the ten days[F(1,10)= 45.438, p< 0.0001], and resulted in 
sensitization or worsening of the disruption of licking induced by olanzapine 
[F(1,10)= 4.112, p<0.0001] (vehicle controls blue circles, lower graph). 
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Figure-10 The effects of subchronic clozapine (red triangles, upper graph), 
risperidone (red triangles, middle graph), and olanzapine (black triangles, lower 
graph)   on lick rhythm. All three compounds had a significant effect on lick rhythm 
each of the ten days, clozapine [F(1,13)= 8.886, p< 0.012], risperidone  [F(1,14)= 
15.965, p< 0.0001], and olanzapine [F(1,9)= 19.220, p< 0.002]. There was no trend 
towards tolerance or sensitization for clozapine [F(1,13)= 0.081, p<0.780], 
risperidone [F(1,14)= 0.475, p<0.503], or olanzapine [F(1,9)= .089, p< 0.769] 
(vehicle controls for each are blue circles). 
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Figure-11 The effects of subchronic clozapine, risperidone, and olanzapine on the 
peak force of licking. Clozapine (red triangles, upper graph) was administered at 20.0 
mg/kg twice daily once 45 minutes before the 3 minute licking session, and once 
twelve hours later. Clozapine significantly effected the peak force of licking each of 
the ten days [F(1,13)=12.337, p<0.003], with no trend towards tolerance or 
sensitization[F(1,13)=0.321, p<0.579], compared to vehicle controls (blue circles, 
upper graph). Risperidone (orange triangles, middle graph) was administered at 2.0 
mg/kg in the same time schedule as clozapine. Risperidone significantly affected the 
peak force of licking each of the ten days [F(1,14)=10.558, p<0.005] and displayed a 
trend towards sensitization [F(1,14)=5.334, p<0.034] (vehicle controls are blue circles 
in the middle graph). Olanzapine (black triangles lower graph) was given at 4.0 
mg/kg twice daily in the same time schedule for clozapine and risperidone. 
Olanzapine significantly effected the peak force of licking each of the ten days 
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[F(1,9)=8.219, p<0.011],  with no trend towards towards tolerance and sensitization 
[F(1,9)=2.424, p<0.139] (vehicle controls are blue circles in the lower graph). 
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